P1175 Multi-centre evaluation of a new hepatitis B surface antigen (HBsAg) assay on the family of Access® immunoassay systems

2007 ◽  
Vol 29 ◽  
pp. S320-S321
Author(s):  
A. Pivert ◽  
A. Ducancelle ◽  
T. Levayer ◽  
F. Descamps ◽  
M. Maniez-Montreuil ◽  
...  
2006 ◽  
Vol 52 (8) ◽  
pp. 1592-1598 ◽  
Author(s):  
Dan Chen ◽  
Lawrence A Kaplan

Abstract Background: The usual criteria for analysis of hepatitis B surface antigen (HBsAg) are detection of HBsAg and result confirmation by antibody neutralization. We observed that with the Immulite 2000 HBsAg assay [Diagnostics Product Corporation (DPC)] a relatively high percentage of weakly reactive (WR) samples did not pass the neutralization step. Methods: For each of 3 lots of Immulite 2000 HBsAg reagent (DPC), we collected and analyzed HBsAg data from ∼3000 to 4000 patient blood samples and compared these data with HBsAg data from 3393 samples tested with the Abbott Auszyme assay. For 127 samples with initially WR detection signals (relative signal/cutoff index of 1.00–2.5) on the Immulite 2000 HBsAg assay, we then measured hepatitis B (HB) viral load and/or other HB serologic markers. Results: The Immulite 2000 HBsAg assay produced more initially reactive results than the Abbott Auszyme method. Many of these reactive samples, however, were WR and did not meet the confirmation criteria in the neutralization test. Moreover, DNA PCR testing indicated that 22 of the 38 WR samples (58%) that did meet the confirmation criteria had no detectable HB viral DNA. Conclusions: Immulite 2000 HBsAg assay results include a unique group of WR samples that are associated with both false-positive and false-negative results, regardless of neutralization status, and require careful interpretation. WR HBsAg samples should be reported as confirmed HBsAg reactive only if the samples not only meet the neutralization criteria but also are positive for other HB serologic markers such as anti-HB core total and anti-HB core IgM.


Kanzo ◽  
2019 ◽  
Vol 60 (7) ◽  
pp. 237-247 ◽  
Author(s):  
Kumiko Oone ◽  
Takako Inoue ◽  
Shigeru Kusumoto ◽  
Tomoyuki Ohike ◽  
Takaaki Goto ◽  
...  

2015 ◽  
Vol 41 (08) ◽  
Author(s):  
E Reuss ◽  
N Evers ◽  
N Dietrich ◽  
J Vollmar ◽  
PM Schneider ◽  
...  

1975 ◽  
Vol 34 (01) ◽  
pp. 083-093 ◽  
Author(s):  
Barry S Coller ◽  
W. B Lundberg ◽  
Harvey R Gralnick

SummaryThe antibiotic vancomycin shares many similarities with ristocetin, an agent noted for its effects on platelets and plasma fibrinogen. Vancomycin did not aggregate platelets as ristocetin, but platelets were incorporated into precipitates induced by vancomycin. Fibrinogen and factor VIII were precipitated from plasma at low concentrations of vancomycin. The precipitated fibrinogen remained clottable. Hepatitis B surface antigen was selectively precipitated from serum and could be recovered from the precipitate. Rabbits receiving bolus intravenous injections of high doses of vancomycin developed hypofibrinogenemia and thrombocytopenia within minutes and often went on to die. Studies with 125I-vancomycin revealed little stable binding of the antibiotic to platelets or fibrinogen. A relationship is suggested between the potent protein precipitating effects and phlebitis at the infusion site commonly associated with vancomycin therapy.


2019 ◽  
pp. 1
Author(s):  
عيظة حميد ◽  
رامى ابن مرضاح ◽  
ريم باوزير ◽  
أحمد بايعشوت ◽  
محمد العكبرى

2018 ◽  
Author(s):  
Ork Vichit ◽  
Joseph Woodring ◽  
Md. Shafiqul Hossai ◽  
Annemarie Wasley ◽  
Shintaro Nagashima ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document